Please assess the completion status of the following clinical trial:

Trial Title: Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients that have locally advanced or metastatic breast cancer. Lesions should not be amenable to surgery or radiation of curative intent~* Hormone therapy-naive~* Estimated life expectancy of more than 12 weeks~Exclusion Criteria:~* Last dose of prior anti-cancer therapy received within 14 days (or longer if required)~* Any eye injury or corneal surgery within 3 months prior to receiving first dose of study drug.~* Currently receiving (and unwilling to discontinue) oestrogen replacement therapy. (last dose \<7 days prior to randomisation)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD8931 40mg (bd) plus anastrozole 1mg (od)
- 2 (Type: EXPERIMENTAL): AZD8931 20mg (bd) plus anastrozole 1mg (od)
- 3 (Type: PLACEBO_COMPARATOR): Placebo (bd) plus anastrozole 1mg (od)

Based on this trial design, predict the completion outcome and termination type (if applicable).